Promising drug trial for thyroid eye disease halted early
NCT ID NCT04737330
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a drug called secukinumab in adults with active, moderate to severe thyroid eye disease, a condition that causes bulging eyes and discomfort. The trial aimed to see if the drug could reduce eye bulging and inflammation. However, the study was stopped early and only 28 people took part, so the results are not conclusive.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Secukinumab
What this could lead to
If this treatment had worked, it could have pointed toward a new option for controlling thyroid eye disease without surgery.
What could go wrong
The trial was stopped early with only 28 participants, so we have very little data. It is unclear if secukinumab is effective or safe for this condition.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for THYROID EYE DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Novartis Investigative Site
Essen, 45147, Germany
-
Novartis Investigative Site
Frankfurt, 60318, Germany
-
Novartis Investigative Site
Freiburg im Breisgau, 79106, Germany
-
Novartis Investigative Site
Göttingen, 37075, Germany
-
Novartis Investigative Site
Mainz, 55131, Germany